David Grimes profile picture

Contact Information

David Grimes, MD, FRCPC
613-761-7021
dagrimes@toh.ca

Please note, Dr. Grimes cannot respond to patient inquiries using this contact information.

Also note that Dr. Grimes is not currently accepting trainees except movement disorder fellows.

1053 Carling Ave, Rm 2200,
Ottawa, ON K1Y 4E9

ORCID logo https://orcid.org/0000-0002-2115-1866

David Grimes

Associate Scientist, Neuroscience
Ottawa Hospital Research Institute
Division Head, Neurology/Medicine
University of Ottawa
Associate Professor, Neurology/Medicine
University of Ottawa
Director, Parkinson's Disease and Movement Disorders Clinic
Ottawa Hospital
Co-Director, Parkinson Research Consortium
University of Ottawa

Research Interests

Clinical research in movement disorders with a focus on Parkinson's disease.  Studies include both industry and investigator driven research exploring a wide variety of issues including clinical care models, biomarkers, observational studies, and the latest pharmacologic treatment options. Sponsors include CIHR, University of Ottawa Brain and Mind Research Institute, Michel J Fox Foundation, Parkinson Research Consortium, and Ontario Brain Institute.

Brief Biography

Dr. Grimes received his Doctorate in Medicine and completed his residency in Neurology at the University of Ottawa. He spent two years at the Toronto Hospital and the Centre for Research in Neurodegenerative Diseases as a research fellow in movement disorders and molecular genetics. He joined the Department of Medicine in Ottawa in 1999 and is the current Chair and Chief of the Division of Neurology, University of Ottawa. His major clinical interests are in the diagnosis and treatment of a wide variety of movement disorders with an emphasis on Parkinson's disease and dystonia.  He has extensive experience with botulinum toxin injections for the treatment of focal dystonia and hemifacial spasm.
He received the Queen’s Diamond Jubilee Medal (2012), nominated by the Parkinson Society Canada for leading the development of the Canadian Guidelines on Parkinson’s disease

Selected Publications

Brodsky M, Swope D, Grimes D.  Factors that affect the diffusion of botulinum toxins. Tremor Other Hyperkinet Mov (N Y). 2012;2. pii: tre-02-85-417-1. Epub 2012 Aug 6  PMID: 23440162

Grimes D, Gordon J, Snelgrove B, et al.  Canadian Guidelines on Parkinson's disease. Can J Neurol Sci. 2012;39:Suppl 4: S1-S30.  PMID: 23126020

Kitada T, Tomlinson JJ, Sio Ao H, Grimes DA, Schlossmacher MG. Considerations Regarding the Etiology and Future Treatment of Autosomal Recessive Versus Idiopathic Parkinson Disease. Curr Treat Options Neurol. 2012;14, (3):230-240, DOI: 10.1007/s11940-012-0175-8.  PMID: 22547255
 
Tahar AH, Chuang R, Steeves T, Jog M, Lang A, Grimes D.  Efficacy and Safety of T2000 in Older Patients with Essential Tremor.  Parkinsonism Relat Disord. 2012 Dec 17. PMID: 23254160

Sinha N, Grimes D, Rogaeva E, Tokuhiro S, Sato C, Woulfe J. Variant Alzheimer disease with spastic paraparesis and supranuclear gaze palsy.  Can J Neurol Sci. 2013 Mar;40(2):249-51.  PMID:23419577

Grimes, David A. Parkinson's Disease Compendium of Therapeutic Choices for its 7th Edition (2014), Editor Barbara Jovaisas

Diseases, conditions and populations of interest





Research and clinical approaches